Thirteen Presentations Include New Analyses of PCSK9 Inhibitor at Upcoming American Heart Association Scientific Sessions THOUSAND OAKS, Calif., Nov. 12, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014 being held Nov. 15-19 in Chicago, including data from studies evaluating evolocumab, […]
Foundation’s Commitment to Science, Technology, Engineering and Math (STEM) Education Surpasses $100 Million Milestone THOUSAND OAKS, Calif., Nov. 12, 2014 /PRNewswire/ — The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe, and, for the first time, Japan. A signature Foundation initiative, the […]
hubbub health one of six nationwide finalists for health care innovation Washington, D.C. NOVEMBER 11, 2014 -– Today at The National Business Coalition on Health (NBCH) annual conference, hubbub health, a software-as-a-service mobile wellness program, will be recognized as a leader in corporate wellness as a finalist in NBCH’s “Innovation” category. NBCH is a non-profit […]
Worldwide trends of aging populations and less healthy lifestyle habits, are contributing to the rise of non-alcoholic fatty liver disease (NAFLD) 1 More than 100 million people are estimated to be suffering from NAFLD (15% to 20% of the populations of advanced industrial nations) 2 This alliance is key to enabling the early development of […]
Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting® and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON, November 11, 2014–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and […]
Brodalumab Meets All Primary and All Key Secondary Endpoints Meets Primary Endpoint of Superiority to Stelara® (ustekinumab) in Achieving Total Skin Clearance (PASI 100) Meets Co-Primary Endpoints Against Placebo THOUSAND OAKS, Calif. and LONDON, Nov. 11, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 […]
Once-Daily Combination Achieves High SVR12 Rates Across Multiple HCV Genotypes BOSTON–(BUSINESS WIRE)–Nov. 11, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of an investigational all-oral pan-genotypic regimen containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi® by the U.S. Food and Drug […]
High Cure Rates in Nearly 800 HCV Patients with Advanced Liver Disease BOSTON–(BUSINESS WIRE)–Nov. 11, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with […]
ATLANTA, NOVEMBER 10, 2014 -– SpendWell Health™ – part of the Cambia Health Solutions group – will be highlighting their innovative online marketplace at the 2014 IHC FORUM West conference taking place November 10-12, 2014 at the Red Rock Resort Spa & Casino in Las Vegas. SpendWell’s online marketplace helps employees with high-deductible health plans […]
THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a […]